NCT02846142View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Healthy Volunteer
Interventions
DRUG

PTI-428

OTHER

Placebo

DRUG

ethinyl estradiol and levonorgestrel

Trial Locations (1)

Unknown

Overland Park

All Listed Sponsors
lead

Proteostasis Therapeutics, Inc.

INDUSTRY

NCT02846142 - Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers | Biotech Hunter | Biotech Hunter